Oxford Global NextGen Omics UK w/ Dr Francesca Mulas

Join Francesca Mulas, Lead Bioinformatics Scientist, for a talk on identifying clinically-relevant sub-populations of patients from omics data.

The Oxford Global NextGen Omics UK conference showcases research, technologies and therapeutic applications across next generation sequencing, clinical diagnostics, single cell and spatial analysis, genome editing and digital PCR. 

Francesca will speak on identifying clinically-relevant patient sub-populations during the Bioinformatics & Advanced NGS Tools & Technologies track, and will focus on precision medicine workflows, and patient stratification and endotyping from omics data.

Find out more →  

Francesca Mulas

Lead Bioinformatics Scientist

Francesca is the Precision Medicine Bioinformatics Lead at BenevolentAI, where her work focuses on building tools to identify disease-relevant patient endotypes from omics data. She holds a PhD and Masters in Biomedical Engineering and Bioinformatics, with a particular focus on applying machine learning and systems biology methods to regenerative medicine.

More Posts

You Might Also Like

BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022